Beta
ManageSearchChatDiscover
353392

Assessing TGF β1 Gene Expression as a Prognostic Marker for Hepatocellular Carcinoma Development in HCV patients receiving Direct-Acting Antiviral (DAAs) Therapy

Article

Last updated: 01 Jan 2025

OverviewSimilar Items

Subjects

-

Tags

Biochemistry

Abstract

Hepatocellular carcinoma (HCC) is a complex and multifactorial disease. There is a considerable risk of developing HCC among HCV patients treated with direct acting antiviral therapies (DAAs). This study attempts to evaluate the role of tumor growth factor beta (TGF-β1) gene expression as a prognostic marker for the development of post-DAAs HCC. Methods: The study contained 220 participants distributed into four groups: de-novo HCC (Group 1, n=70), HCC after DAAs treatment (Group 2, n=50), HCV patients treated with DAAs without complications (Group 3, n=60), and a control group (Group 4, n=40). TGF-β1 gene-expression by Real Time PCR, routine investigations and clinical assessment were assessed for all participants. HCC de-novo exhibited significantly higher TGF-β1 gene expression than the other groups (P value 0.05. Overall survival analysis showed no significant association between TGF expression in either de novo or post-DAAs developed HCC. In conclusion, serum TGF-β1 emerges as a promising marker for the occurrence of post-DAAs Hepatocellular carcinoma, exhibiting high sensitivity and specificity. Regular monitoring of TGF-β1 levels in hepatitis C virus cases following DAAs treatment can serve as a potential marker for HCC development.

DOI

10.21608/ejchem.2024.273216.9395

Keywords

Keywords: HCV infection, HCC, DAAs, TGF-β1

Authors

First Name

Samar Ebrahim

Last Name

Ghanem

MiddleName

-

Affiliation

Department of Clinical Biochemistry and Molecular Diagnostics, National Liver Institute, Menoufia University

Email

-

City

-

Orcid

-

First Name

Ibrahim El Tantawy

Last Name

El Sayed

MiddleName

-

Affiliation

Chemistry Department, Faculty of Science, Menoufia University

Email

-

City

-

Orcid

-

First Name

Ashraf A.

Last Name

Basuni

MiddleName

-

Affiliation

Department of Clinical Biochemistry and Molecular Diagnostics, National Liver Institute, Menoufia University

Email

ashrabasuni50@gmail.com

City

CAIRO

Orcid

https://orcid.org/00

First Name

Dalia

Last Name

El Sabaawy

MiddleName

-

Affiliation

Department of Clinical Pharmacy, Faculty of Pharmacy, Menoufia University

Email

-

City

-

Orcid

-

First Name

Abd El- Hamid A.

Last Name

Ismail

MiddleName

-

Affiliation

Department of Organic Chemistry, Faculty of Science, Menoufia University

Email

-

City

-

Orcid

-

First Name

Rofaida Mohamed

Last Name

Elhawary

MiddleName

-

Affiliation

Chemistry Department, Faculty of Science, Menoufia University

Email

-

City

-

Orcid

-

First Name

Nashwa Abuel-Fetuh

Last Name

Shebl

MiddleName

-

Affiliation

Hepatology and Gastroenterology department, National Liver Institute, Menoufia University

Email

-

City

-

Orcid

-

First Name

Warda Othman

Last Name

Saad

MiddleName

-

Affiliation

Hepatology and Gastroenterology department, National Liver Institute, Menoufia University

Email

-

City

-

Orcid

-

Volume

67

Article Issue

11

Related Issue

50157

Issue Date

2024-11-01

Receive Date

2024-03-05

Publish Date

2024-11-01

Page Start

71

Page End

81

Print ISSN

0449-2285

Online ISSN

2357-0245

Article File

EJCHEM_Volume 67_Issue 11_Pages 71-81.pdf

PDF . 5.0MB

Link

https://ejchem.journals.ekb.eg/article_353392.html

Detail API

https://ejchem.journals.ekb.eg/service?article_code=353392

Order

353,392

Type

Original Article

Type Code

297

Publication Type

Journal

Publication Title

Egyptian Journal of Chemistry

Publication Link

https://ejchem.journals.ekb.eg/

MainTitle

Assessing TGF β1 Gene Expression as a Prognostic Marker for Hepatocellular Carcinoma Development in HCV patients receiving Direct-Acting Antiviral (DAAs) Therapy

Details

Type

Article

Created At

30 Dec 2024